Last reviewed · How we verify
Carbon-14 labeled HSK39297
Carbon-14 labeled HSK39297 is a Small molecule drug developed by Haisco Pharmaceutical Group Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | Carbon-14 labeled HSK39297 |
|---|---|
| Sponsor | Haisco Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carbon-14 labeled HSK39297 CI brief — competitive landscape report
- Carbon-14 labeled HSK39297 updates RSS · CI watch RSS
- Haisco Pharmaceutical Group Co., Ltd. portfolio CI
Frequently asked questions about Carbon-14 labeled HSK39297
What is Carbon-14 labeled HSK39297?
Carbon-14 labeled HSK39297 is a Small molecule drug developed by Haisco Pharmaceutical Group Co., Ltd..
Who makes Carbon-14 labeled HSK39297?
Carbon-14 labeled HSK39297 is developed by Haisco Pharmaceutical Group Co., Ltd. (see full Haisco Pharmaceutical Group Co., Ltd. pipeline at /company/haisco-pharmaceutical-group-co-ltd).
What development phase is Carbon-14 labeled HSK39297 in?
Carbon-14 labeled HSK39297 is in Phase 1.